Literature DB >> 8824565

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

M S Kang1, H J Lee, J H Lee, J L Ku, K P Lee, M J Kelley, Y J Won, S T Kim, J G Park.   

Abstract

It has been known that the incidence of p53 mutation is very rare in HBX-positive primary human hepatocellular carcinoma (HCC) tissues. The frequency of p53 mutation, however, in established cell lines with integrated HBV DNA and/or HBX has not been well studied. To know p53 mutational frequency, and to investigate whether the presence of HBX DNA sequence correlates with the absence of p53 mutation in the established HCC cell lines, we studied the p53 mutation and the presence of HBX sequence in 12 recently characterized HCC cell lines. As a result, all 12 (100%) lines showed mutation in the p53 gene. Three (25%) cell lines had transversion of codon 215 while no mutation of codon 249 was found. In contrast with previous reports, although HBX DNA was present in 11 cell lines, p53 mutation had occurred, indicating that the presence of HBX viral DNA does not correlate with a lack of p53 mutation in established HCC cell lines. Our results suggest that the frequency of p53 mutation is extremely high even in HBX DNA positive HCC cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824565     DOI: 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.

Authors:  Tae-Jin Song; David P Eisenberg; Prasad S Adusumilli; Michael Hezel; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

2.  Establishment and characterization of six human gastric carcinoma cell lines, including one naturally infected with Epstein-Barr virus.

Authors:  Ja-Lok Ku; Kyung-Hee Kim; Jin-Sung Choi; Sung-Hee Kim; Young-Kyoung Shin; Hee Jin Chang; Jae-Moon Bae; Young-Woo Kim; Jun Ho Lee; Han-Kwang Yang; Woo-Ho Kim; Seung-Yong Jeong; Jae-Gahb Park
Journal:  Cell Oncol (Dordr)       Date:  2012-02-24       Impact factor: 6.730

3.  Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA.

Authors:  Jae-Ho Lee; Ja-Lok Ku; Young Jin Park; Kuhn-Uk Lee; Woo-Ho Kim; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

4.  Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes.

Authors:  Ja-Lok Ku; Kyung-Hee Kim; Jin-Sung Choi; You-Kyung Jeon; Sung-Hee Kim; Young-Kyoung Shin; Tae-You Kim; Yung-Jue Bang; Woo Ho Kim; Jae-Gahb Park
Journal:  Cell Oncol (Dordr)       Date:  2011-02-02       Impact factor: 6.730

5.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

6.  Establishment and characterisation of six human biliary tract cancer cell lines.

Authors:  J-L Ku; K-A Yoon; I-J Kim; W-H Kim; J-Y Jang; K-S Suh; S-W Kim; Y-H Park; J-H Hwang; Y-B Yoon; J-G Park
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

7.  Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population.

Authors:  Jae Woo Jung; So-Mi Yoon; Subin Kim; Yun-Hui Jeon; Byung-Hak Yoon; Su-Geun Yang; Min Kyoung Kim; Senyon Choe; Mario Meng-Chiang Kuo
Journal:  Oncotarget       Date:  2016-11-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.